Moreover, whatever the molecular pathway implied, Naftopidil is able to induce the BH3-only Bim, Noxa and Puma in ovarian carcinoma which sensitizes to anti-Bcl-xL strategies or to Trametinib (Supplementary Fig. S8). The gene discussed is BCL2L1; the disease is ovarian carcinoma.